Dataset Information

Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research.

ABSTRACT: Coronavirus disease 2019 (COVID-19), currently a worldwide pandemic, is a viral illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The suspected contribution of thrombotic events to morbidity and mortality in COVID-19 patients has prompted a search for novel potential options for preventing COVID-19-associated thrombotic disease. In this article by the Global COVID-19 Thrombosis Collaborative Group, we describe novel dosing approaches for commonly used antithrombotic agents (especially heparin-based regimens) and the potential use of less widely used antithrombotic drugs in the absence of confirmed thrombosis. Although these therapies may have direct antithrombotic effects, other mechanisms of action, including anti-inflammatory or antiviral effects, have been postulated. Based on survey results from this group of authors, we suggest research priorities for specific agents and subgroups of patients with COVID-19. Further, we review other agents, including immunomodulators, that may have antithrombotic properties. It is our hope that the present document will encourage and stimulate future prospective studies and randomized trials to study the safety, efficacy, and optimal use of these agents for prevention or management of thrombosis in COVID-19.

SUBMITTER: Bikdeli B

PROVIDER: S-EPMC7516364 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research.

Bikdeli Behnood B Madhavan Mahesh V MV Gupta Aakriti A Jimenez David D Burton John R JR Der Nigoghossian Caroline C Chuich Taylor T Nouri Shayan Nabavi SN Dreyfus Isaac I Driggin Elissa E Sethi Sanjum S Sehgal Kartik K Chatterjee Saurav S Ageno Walter W Madjid Mohammad M Guo Yutao Y Tang Liang V LV Hu Yu Y Bertoletti Laurent L Giri Jay J Cushman Mary M Quéré Isabelle I Dimakakos Evangelos P EP Gibson C Michael CM Lippi Giuseppe G Favaloro Emmanuel J EJ Fareed Jawed J Tafur Alfonso J AJ Francese Dominic P DP Batra Jaya J Falanga Anna A Clerkin Kevin J KJ Uriel Nir N Kirtane Ajay A McLintock Claire C Hunt Beverley J BJ Spyropoulos Alex C AC Barnes Geoffrey D GD Eikelboom John W JW Weinberg Ido I Schulman Sam S Carrier Marc M Piazza Gregory G Beckman Joshua A JA Leon Martin B MB Stone Gregg W GW Rosenkranz Stephan S Goldhaber Samuel Z SZ Parikh Sahil A SA Monreal Manuel M Krumholz Harlan M HM Konstantinides Stavros V SV Weitz Jeffrey I JI Lip Gregory Y H GYH

Thrombosis and haemostasis 20200530 7

Coronavirus disease 2019 (COVID-19), currently a worldwide pandemic, is a viral illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The suspected contribution of thrombotic events to morbidity and mortality in COVID-19 patients has prompted a search for novel potential options for preventing COVID-19-associated thrombotic disease. In this article by the Global COVID-19 Thrombosis Collaborative Group, we describe novel dosing approaches for commonly used antithromb ...[more]

PMID: 32473596

Similar Datasets

Project description:Coronaviruses are pleomorphic, enveloped, or spherical viruses, which have a size ranging from 80 to 120 nm. These viruses act on receptors that cause the triggering of fusion. Coronaviruses were first described after cultivation from patients with common colds by Tyrell and Bynoe in 1966. There are various subtypes of coronavirus, 7 out of these can cause infection in human beings. The Alpha subtype is responsible for mild infection showing symptoms or infection without any prevailing symptoms. On the other hand, the beta subtype is responsible for very serious diseases leading to fatality. The lineage of this novel SARS-CoV-2 falls under the beta lineage of the beta coronavirus which has been observed to have a relation to the MERS and SARS coronavirus. In the Huanan market selling seafood, the transition of this novel virus in humans from animals has occurred. It has the potential to be the cause of widespread fatality amongst the people of the globe. On August 16, 2020, the World Health Organisation had reported 2,1294,845 cases which are confirmed to date out of which 413,372 deaths have occurred. Currently, no targeted antiviral vaccines or drugs to fight against COVID-19 infection have been approved for use in humans. This pandemic is fast emerging and drug repurposing is the only ray of hope which can ensure quick availability. Vaccine development is progressing each day with various platforms such as DNA, Live Attenuated Virus, Non-Replicating Viral Vector, Protein Subunit, and RNA, being utilized for the development. COVID-19 attacks the immune system of the host & this can result in a cytokine storm. As a result, various herbal agents both acting as antivirals and immunomodulatory can also be used. Convalescent Plasma Therapy and Mesenchymal Stem Cell therapy are also being explored as a plausible therapeutic. There remains a considerable unmet need for therapeutics to be addressed. The development and availability of accessible and efficient therapy are essential for the treatment of patients. This review discusses the epidemiology, pathogenesis, the tale of origin, and transmission of COVID-19 or Sars-Cov2 virus and gives evidence of potential therapeutic agents that can be explored to cast away this pandemic.

Dataset Information

Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research.

Publications

Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure